Trial Profile
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Registrational; Therapeutic Use
- Sponsors Romark Laboratories
- 04 Apr 2019 Status changed from recruiting to completed.
- 28 Aug 2018 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 28 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.